Novo Nordisk announced on 24 November 2025 the end of its phase 3 EVOKE and EVOKE+ trials, which investigated oral semaglutide – the active ingredient in Rybelsus, approved for type 2 diabetes – as a…… Semaglutide Trial Ends...
You must be a Free member to access this content.
At the European Academy of Neurology Congress in Helsinki, researchers unveiled a groundbreaking blood test that could revolutionize Alzheimer’s disease management by identifying patients with mild cognitive impairment (MCI) likely to progress rapidly to severe…… Ground-breaking Alzheimers blood test...
Two innovative Alzheimer’s drugs, donanemab and lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending independent living, by…… Donanemab and Lecanemab rejected for the NHS...